HIV has plagued humans for at least 30 years, infecting 60 million people and causing >25 million deaths. AIDS patients can be effectively treated with highly active antiretroviral therapy (HAART), which usually comprises a combination of three anti-HIV drugs 1 . However, the cost of current HAART is prohibitive in developing countries. In addition, long-term HAART can have serious side effects such as lipodystrophy, hyperglycemia, pancreatitis and liver toxicity 2 . New therapies are needed to expand the current HAART repertoire, to provide hope for a cure and to reduce the cost of treatment and side effects 3, 4 .
Combination therapies are also widely used to treat other infections including hepatitis C virus, malaria and bacterial infections such as pneumonia, in addition to noninfectious diseases such as cancer and asthma 5 . Major benefits of combination therapy include a substantially reduced chance of evolving drug resistance, improved efficacy and reduced side effects 6 . The large number of possible combinations from existing drugs provides an untapped resource for developing new treatments. Exploiting this resource could accelerate the drug development process as drugs in current or past use have favorable pharmacological properties. However, even for pairwise combinations of a modest number of drugs, there are so many possible combinations it makes a systematic search difficult without an efficient method to multiplex pairs. For example, for 10 drugs, there are 45 pairwise combinations; for 100 drugs, 4,950; and for 1,000 drugs, 499,500.
Systematic searches for synergistic drug combinations have been done previously in industrial settings using exhaustive combinations 7, 8 , but the high cost of this method prevents wide adoption. Pooled screening methods have been explored to identify enzyme inhibitors 9 and to look for synergistic anti-inflammatory compound pairs 10 , although the latter study did not yield any novel pairs. We have developed MuSIC, a pooled screening method, to screen a large collection of diverse FDA-approved or clinically tested compounds. The MuSIC screening library was designed to contain ten compounds in each well of a 384-well plate and cover all the possible pairwise combinations among these compounds using <3% of the number of wells needed in a standard pairwise screen. For pools that contained potentially strong synergistic interactions, we deconvoluted each of them into 45 drug pairs in a secondary screen to identify efficacious drug pairs. Subsequently, we performed dose titration of the drug pairs to verify whether the drugs did act in synergy (Fig. 1a) . We validate our method using cell-based models of the HIV life cycle and show that it was effective at identifying pairwise combinations that have anti-HIV activity.
RESULTS

Design, construction and screening of the MuSIC library
We selected 1,000 compounds from two commercially available drug libraries and the US National Institutes of Health Clinical Collection of compounds that have been tested clinically (Supplementary Table 1) . We did a preliminary drug screen on our cell line to eliminate potentially toxic chemicals. We also eliminated compounds that were (i) mainly used topically; (ii) cytotoxic; (iii) structurally related to compounds already selected and therefore redundant; (iv) HAART drugs and other antivirals that might dominate a pool. We aimed to use a minimal number of wells to efficiently assess all the possible pairs among the 1,000 compounds. We chose a pool size of ten because of the tradeoff between the number of pools required and systematic identification of synergistic drug pairs targeting HiV A r t i c l e s the amount of deconvolution. As it is not possible to construct pools of 10 drugs each such that every pair in the 1,000-compound library occurs in exactly one pool, we developed a heuristic algorithm that guarantees that each drug pair occurs in at least one pool and aims to minimize the number of redundant pairs (Fig. 1a, Supplementary  Fig. 1 and Supplementary Algorithm). This heuristic algorithm produced 13,106 pools, which is 2.6% of the number of wells needed for testing all pairwise interactions separately and only 18% larger than the theoretical lower bound of 11,100 pools. The arrayed library consisted of 45 384-well plates in which each compound was present at a concentration of 0.1-0.2 mg/ml in DMSO (Supplementary Fig. 2) .
We used HeLa cell-derived MAGI cells that express the CD4 receptor 11 , and the IIIB strain of HIV for our screening assay. Our screen uses a two-part assay modified from our previously reported short interfering RNA screen (Fig. 1b) 12 . Part 1 of the assay consists of incubating cells for 18 h with drugs and then infecting them with virus. After 48 h, HIV infectivity is measured by detection of the HIV p24 antigen using immunostaining and automated fluorescence imaging. Nuclear staining and imaging are also carried out on the same plates to assess cell proliferation and cytotoxicity of the drugs. Part 1 measures the viral infection steps from entry to protein translation. In part 2 of the assay the supernatant from part 1 is transferred to fresh cells and, 48 h later, those cells are stained for p24 and nuclei. This quantifies the number of new viral particles produced in part 1 and both reinforces the results of part 1 and complements it by detecting later stages of the HIV life cycle including viral assembly, budding and infectivity. This two-part assay strategy was optimized using the known anti-HIV drugs azidothymidine (AZT) and nevirapine as positive controls and DMSO as the negative control ( Fig. 1c and  Supplementary Fig. 3 ).
MuSIC screening identifies synergistic anti-HIV drug pairs
From the primary screen of the pooled library using the two-part assay done in triplicate (Supplementary Table 2 ), we selected 288 pools for deconvolution based on their low infection rate and low cytotoxicity, resulting in 12,904 unique drug pairs. We constructed a secondary library to deconvolute the 288 pools and identify potent drug pairs. We used another heuristic algorithm to design the layout of the plates of the secondary library to account for the high variability in drug representation in the secondary library and the limit on available drug volume ( Supplementary Fig. 2 and Supplementary Algorithm). The secondary screen was carried out on this secondary library, which we screened in triplicate using the same two-part assay (Supplementary Table 3 ). We validated the results of the secondary screen by selecting the top 116 pairs that reduced the infection rate in either the part 1 or the part 2 assay by at least 50% and carrying out concentration titration experiments. Of the 116 pairs, 104 (90%) reduced the HIV infection rate by ≥50% in the part 2 assay in at least one concentration combination used in the titration (Supplementary Table 4) .
To measure synergy between drugs, we used two popular models, Bliss independence 13 and higher single activity (HSA) 7 . The Bliss model is based on probability theory and assumes that when two drugs are independent, their combinatorial effect should be the multiplication of their individual effects. The HSA model defines synergy as a combinatorial effect that is larger than any of the individual drug's effects at the same concentrations as present in the mixture. To increase the stringency of our criteria, we required that at least three dose combinations produced ≥10% reduction of normalized HIV infection over that predicted by the synergy models. According to the Bliss model, 66 of the 116 pairs (57%) showed synergy using these criteria. For the HSA model, 77 pairs (66%) were synergistic and 41 pairs (35%) were synergistic using both models (Supplementary Table 5 and Supplementary Figs. 4 and 5) . Notably, a top pool (producing among the largest reductions in HIV infection rates) identified in the primary screen (Fig. 2a) produced a top-ranked pair in the secondary screen, comprising the glucocorticoid drug betamethasone and an anti-protozoal drug NTZ (Fig. 2b) , indicating the effectiveness of this primary and secondary screening strategy. We also observed that multiple drugs in the top pairs from the part 1 of the secondary screen belonged to a small set of functional groups including glucocorticoids, 
npg
A r t i c l e s nonsteroidal anti-inflammatory drugs (NSAIDs) and anti-cholinergic drugs. The four glucocorticoids present in our library appeared most frequently among the top pairs.
A separate screen validates the MuSIC strategy To systematically validate the MuSIC method, we performed a separate screen to directly look for drugs that synergize with the glucocorticoid prednisolone (PDN), as glucocorticoids were highly represented in the top pairs. This screen was done using the part 1 assay with each well containing PDN and one of the 1,000 drugs in the MuSIC library. We found that NTZ consistently displays the highest synergy with PDN (Fig. 2c) . In addition, among the top 15 hits from this direct screen (Z score < -1.5), 7 were also scored as hits in the MuSIC screen (Z score < -1.5), a discovery rate of 46.7% (P < 10 −13 , binomial test) (Supplementary Tables 3 and 6 ). Given the high complexity and multiplicity of the screen, these findings clearly demonstrate that the MuSIC strategy can effectively identify strongly synergistic drug pairs.
Validation of the synergy of glucocorticoids and NTZ Glucocorticoids are widely used anti-inflammatory drugs and their inhibition of HIV has been primarily attributed to reduction of HIV-long terminal repeat (LTR)-driven transcription 14, 15 . In clinical trials, glucocorticoids have been shown to be protective against CD4 + T-cell loss due to HIV infection 16, 17 . NTZ was approved for treating cryptosporidiosis in 2004 and later found to have activities against the hepatitis C 18 , hepatitis B 18 and influenza A viruses 19 in cellular assays, but its anti-HIV activity has not been previously reported.
The synergy between these two drugs was confirmed by two distinct methods to quantify drug synergy: the Bliss independence model 13 and the combination index method based on the Loewe additivity model (CI) 20 , which assumes that the combination should have the same effect as one of the single agents, but at a higher concentration corresponding to the addition of equally effective doses 6 . The combinatorial effects of a glucocorticoid and NTZ are substantially larger at multiple doses than those predicted by the Bliss model (Fig. 2d) .
Combination indices calculated at three activity levels and two dose ratios all indicate strong (CI < 0.3) or very strong (CI < 0.1) synergy between the glucocorticoid PDN and NTZ ( Fig. 2e-g ). This synergy is achieved with no cytotoxicity as measured by cell proliferation in the 3-day assay (Supplementary Fig. 6 ). We confirmed the synergy between a glucocorticoid and NTZ in a T-cell line (Jurkat cells) using a reporter assay (Supplementary Fig. 7 ). We also tested the anti-HIV effect of PDN and tizoxanide (TIZ, the metabolic product and active form of NTZ) in primary peripheral blood mononuclear cells (PBMCs). In the PBMC assay, p24 enzyme-linked immunosorbent assay (ELISA) was used to quantify HIV replication 7 d after infection. The synergy of PDN and TIZ in anti-viral activity is clear; for example, 2 µM TIZ alone reduces infection by 10% and 2 µM PDN alone, by 51%, but combined, they reduce infection by 79% (Fig. 2h) . The toxicity in this stringent 7-day assay due to PDN is mild; for example, at 10 µM, the reduction of viability measured by CellTiter Glo assay is about 27%. Notably, there is no additional toxicity caused by combining TIZ with PDN ( Supplementary Fig. 8 ). 
A r t i c l e s
Glucocorticoids and NTZ target different steps of the HIV life cycle
We next tested combinations of PDN or NTZ with known anti-HIV drugs for synergy. Notably, although both PDN and NTZ synergize with the HIV integrase inhibitor raltegravir (Fig. 3a,b) , only PDN synergizes with the nucleoside reverse transcriptase inhibitor AZT (Fig. 3c) . NTZ displays an exact Bliss independence in combination with AZT (Fig. 3d) . Similar patterns were observed with the nonnucleoside reverse transcriptase inhibitor efavirenz (Fig. 3e,f) and no synergy was detected between AZT and efavirenz ( Fig. 3g) . We also performed combination index analysis of the data ( Supplementary  Fig. 9 ). This model seems to be more lenient than the Bliss model for judging synergy as all of the analyzed pairs have a CI 50 (combination index at 50% efficacy level) below 1, indicating synergy. Nevertheless, we consistently observed that the CI 50 of NTZ in combination with other drugs was very similar to those of reverse transcription inhibitors (AZT or efavirenz) in combination with the same drugs, whereas PDN has a much lower CI 50 . We suspect the similarity of synergy patterns of NTZ and reverse transcription inhibitors might be due to their overlapping mechanisms of action, as a previous study found a correlation between the interaction profile of a drug and its mechanism of action 21 . To test this hypothesis, we infected MAGI cells using vesicular stomatitis virus envelope glycoprotein (VSV-g) pseudotyped HIV NL4-3 virus and measured the product of HIV reverse transcription (late RT) and its derivative (2-LTR circles) by quantitative real time PCR. NTZ markedly inhibited reverse transcription, whereas PDN had no effect (Fig. 3h) . The same experiment was carried out using the T-cell line SupT1 and similar results were obtained ( Supplementary Fig. 10 ). We also used a β-lactamase (BlaM) assay to measure viral entry 22 and found that NTZ does not affect the entry step ( Supplementary Fig. 11) ; therefore NTZ works after viral entry but before, or at, reverse transcription. By contrast, glucocorticoids inhibited a step later than reverse transcription, consistent with prior studies that showed that a glucocorticoid reduces HIV-LTR-driven transcription 14, 15 . No inhibition of reverse transcription by NTZ was observed using an in vitro reverse transcription enzymatic assay (Supplementary Fig. 12 ), indicating that any inhibition is indirect. We conclude that synergy between NTZ and PDN likely resulted from targeting different steps in the HIV life cycle.
Systematic analysis of synergistic drug pairs
The MuSIC screen examined almost half-a-million drug pairs. To extract drug-drug interaction information from this screen, we performed a computational analysis of the result of the secondary screen of drug pairs. We took advantage of the fact that each drug was present in multiple pairs in the secondary library to derive an average effect for each drug and to estimate the synergy, additivity or antagonism between drugs. Adapting a previously developed scoring method 23 , we derived a drug-drug interaction network in terms of anti-HIV activity and synergy between drugs. Figure 4 shows the extracted networks of drugs that ranked tops in terms of anti-viral activity and degree of synergy with other drugs in the part 1 and 2 assays (see Online Methods for the scoring method and drug selection criteria), which indicates anti-HIV activity both in combination and alone. We constructed two networks, one for drugs that scored in the part 1 assay, and one for those that scored only in the part 2 assay. Drug pairs in the 'part 1' network reduced infection rates in both the part 1 and part 2 assays, indicating their effects early in the assay. For the 'part-2-only' network, we required the pairs to have a strong anti-viral activity in the part 2 assay but not in the part 1 assay, thus reflecting their functions at the later stages of the viral life cycle. We also required the selected drugs to have more than one potent synergistic interaction with other drugs, which simplified the network depiction and increased the confidence of the network shown. The part 1 network enriched for drugs with previously demonstrated anti-HIV activity (P < 10 −12 , χ 2 test) (Fig. 4 and Supplementary Table 7) . In addition, functional annotation analysis showed that several drug classes had 
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A r t i c l e s multiple drugs represented including glucocorticoids, NSAIDs, muscarinic cholinergic receptor antagonists and quinolone. Another feature of this network is the enrichment for drugs that have anti-inflammatory properties (P < 10 −4 , χ 2 test). The two widely used antiinflammatory drug categories were highly enriched with four glucocorticoids and five NSAIDs. Other drugs in the network with known anti-inflammatory functions included ascorbic acid, rapamycin, a statin drug, a PDE4 inhibitor (rolipram) and a β-adrenoreceptor agonist (Supplementary Table 8 ). By contrast, the part-2-only network comprised very different drug groups. Only one drug in this network has previously been shown to have anti-HIV activity, probably because previous drug screens primarily examined the early steps of viral infection. This part 2 assay identified novel targets for HIV therapies that inhibit viral assembly and release. The different targets of the drugs in the part 1 and 2 networks suggested that there might be synergy between these two groups, which was indeed the case (Fig. 4) .
DISCUSSION
We report the development of a drug screening method to identify drug-drug interactions among 1,000 FDA-approved or clinically tested drugs that collectively represent a large portion of the chemicals in current clinical use. We demonstrate that this method is effective at selecting drug pairs with strong efficacy and synergy as validated by concentration titration experiments and an independent validation screen. Although the effects of some pairs were inevitably missed owing to the presence of additional drugs in the initial pool assay that interfere with synergistic effects and the inherent variability of large-scale screens, this method seems to be robust, based on a separate validation screen, and has an estimated discovery rate of 46.7%. In addition to the detection of drugs with previously known activity against HIV, we identified several previously unknown anti-HIV reagents that warrant further investigation. This is especially true for the pairs that have effects in the late viral life cycle part of the part 2 assay of the screen. In addition, we demonstrate a significant enrichment of anti-inflammatory drugs in the anti-HIV synergistic drug network. Notably, multiple studies have suggested that chronic inflammation is associated with disease progression in AIDS patients [24] [25] [26] [27] [28] [29] . Furthermore, clinical studies of AIDS patients on HAARTs have revealed serious health problems caused by HIVinduced chronic inflammation 30 . Whereas chronic inflammation contributes to infection-associated pathology, our results suggest that HIV propagation may be dependent on inflammation given the enrichment of anti-inflammatory agents in our screen. Studies in primates support the notion that suppression of immune activation may be a major protection mechanism that prevents disease progression in the natural hosts of simian immunodeficiency virus 31 . Thus, antiinflammatory therapies for AIDS should be investigated not only for relief of virus-associated pathology, but also to inhibit virus propagation. The MuSIC screening methodology not only identifies efficacious drug pairs, but also provides biological insight by producing drug-drug interaction networks. We envision that MuSIC could be used for a wide variety of disease-relevant screens, thereby allowing the efficient repositioning of drugs and drug pairs that can be rapidly moved into the clinic.
METHODS
Methods and any associated references are available in the online version of the paper. 
A r t i c l e s
Note: Supplementary information is available in the online version of the paper.
ONLINE METHODS
Construction of the library. We purchased three drug libraries: the US Drug Collection (Microsource Discovery Systems), the FDA-Approved Drug Library (Enzo Life Sciences) and the US National Institutes of Health (NIH) Clinical Collection. The 2,130 total compounds were resuspended in DMSO at a concentration of 2 mg/ml (US drug collection and FDA approved drug library) or 5 mg/ml (NIH Clinical Collection). One thousand of the 2,130 compounds were selected based on a literature search as well as a single-drug screening using the same screening protocol described below to help eliminate topical compounds, toxic compounds or known HARRT anti-HIV compounds (the list of the 1,000 drugs is shown in the Supplementary Table 1) . Among 1,000 drugs, there exist 499,500 distinct drug pairs (1,000*999/2). The primary library plates were created by combining 10 drugs into each well, which allows testing of 45 distinct drug pairs at a time rather than a single pair. In a theoretical best-case scenario in which no drug pair is repeated, this would reduce the number of tests by 45-fold to 11,100. However, constructing a set of 10-drug wells such that each drug pair appears exactly once is not possible, and no formulation of an optimal solution exists to the best of our knowledge. To address this, we developed a heuristic algorithm (Supplementary Algorithm), which aims to minimize the total number of wells needed to cover all pairs, given (i) the total number of drugs and (ii) the number of drugs that can be multiplexed in each well.
The heuristic algorithm builds one well at a time by successively adding the next "best" drug to the well. The best drug d is determined by the number of distinct drug pairs that would result if d were added to the well. If multiple drugs are tied by this criterion, we then consider the number of drugs with which d has already been paired n d . If none of the tied drugs would produce a new drug pair-which occurs, for example, when the very first drug is added to a well-then we break the tie by choosing the drug d with the minimum n d value. However, if adding any of the tied drugs does produces a previously unseen drug pair, we break the tie by choosing the drug d which maximizes n d . Intuitively, this policy should select drugs with high potential to form previously unseen drug pairs and should also "finish off " those drugs that have only a few more pairs to satisfy. If the second criterion again produces a tie, it is broken by random selection. The heuristic continues to build wells until all distinct drug pairs have been included in at least one well. When drugs are multiplexed 10 at a time, the heuristic produces solutions with roughly 13,100 wells, or around 20% more wells than the theoretical minimum of 11,100 (Supplementary Fig. 1) . A separate heuristic algorithm (Supplementary Algorithm) is used to distribute these wells over a set of 384-well plates for screening.
The aim of the second heuristic algorithm is to distribute drugs over a set of plates in a reasonably uniform manner. In the following discussion, the representation R d,p of a drug d on a plate p is the number of wells on p that contain d. The maximum drug representation (MDR) of a plate p is the maximum R d,p over all d. The heuristic algorithm works by controlling both the MDR and the variance in drug representation on each plate in the set. Source plates used in this study were created with equal volumes for every drug. Therefore, if one plate called for 20 wells containing drug d but the remaining drugs each appeared in only 10 wells, the drug source must contain a 20-well source volume for every drug-which is a waste for all but d. By keeping the required drug volume approximately equal within each plate, we simplify the process of creating the source plates and minimize wasted source volume.
With the two parameters MDR target and MDR limit specified by the user, the heuristic algorithm attempts to populate 294 wells of each 384-well plate: the first and last row and the first, last and 12th column are left empty for controls. The heuristic starts with the solution set of wells S defined by the initial design. To create the next plate, we iteratively select the well that minimizes | MDR -MDR target | and removes it from S, until the plate is filled. If there is a tie, the first well that satisfies the criterion is chosen. The heuristic terminates when either S becomes empty or it becomes impossible to choose a well from S without breaking the user-defined MDR limit parameter on maximum representation.
The primary library (10 drugs per well) was constructed from the stock library using a Biomek FX robot (Beckman Coulter). The final stock concentration for each drug in each well of the primary library is 0.2 mg/ml (US Drug Collection and FDA-Approved Drug Library) or 0.1 mg/ml (NIH Clinical Collection).
Candidate pools from the primary screen are identified based on the infection rate. From the part 1 assay, a pool was selected for deconvolution if (i) it reduced infection rate by over 50% of the plate average in the part 1 assay; and (ii) it did not reduce cell number in the part 1 assay by 50% or more. From the part 2 assay, a pool was selected for deconvolution if (i) it reduced infection rate by over 70% of the plate average in the part 2 assay but did not reduce infection rate by over 20% of the plate average in the part 1 assay; and (ii) it did not reduce cell numbers in the part 1 assay by 50% or more. This way, we could select those pools that only reduce infection rate in the part 2 assay, which indicates anti-viral activity targeting the late steps of viral life cycle like viral assembly and budding. Each selected pool was deconvoluted to produce up to 45 distinct drug pairs, which were then screened individually.
To deconvolute the hits discovered in the primary screen, we created pair library plates by combining the remaining drug volume from the source plates to build the primary library (Supplementary Fig. 2) . The high variability in drug representation and the limit on available drug volume made it necessary to carefully distribute the 12,904 pairs over the 45 newly created plates. To this end, we created a simple heuristic that distributes drug pairs over the 45 pair plates while maintaining an upper bound on the maximum number of occurrences on each plate. To conserve our restricted library, we aimed for a very low MDR. This method created a set of pairwise plates for which the majority had very low (~3) MDR per plate; however, the remaining plates were heavily enriched for the highly represented compounds and thus had a very high MDR. To cover these highly represented compounds, additional chemicals were purchased to supplement the stock library. The construction of the library was done primarily using the Biomek FX robot, although some of the deconvolution was performed manually due to the limitations of some drug stocks. The secondary library of drug pairs for deconvolution was constructed from 5 × diluted source library so that the final stock concentration for each drug in each well remained 0.2 mg/ml or 0.1 mg/ml, to match the concentration of the primary library.
Screening protocol. The screen was done using 384-well black polystyrene tissue culture plates with clear bottoms (Corning, catalog # 3712). For the part 1 assay, 700-1,000 MAGI cells (NIH AIDS Research & Reference Reagent Program or NARRRP, contributed by Michael Emerman) 11 were plated in each well in 20 µL DMEM media supplemented with 10% fetal bovine serum and 2 mM l-glutamine, 50 U/ml of penicillin and 50 µg/ml streptomycin. One day after plating, 100 nL of each compound or compound mixture was transferred into each well of the plate using a custom designed robot constructed by the Institute of Chemistry and Chemical Biology (http://iccb.med.harvard.edu/ technology-resources/screening-facility/pin-transfer-of-compounds-to-assayplates/#Epson). The final concentration of each drug was 0.5-1 µg/ml. 1 µL of DMSO, AZT and nevirapine diluted in DMEM was added in the 12th column in triplicate using multichannel pipettes to make the final concentration of AZT and nevirapine 1 µg/ml and DMSO 0.5%. Each library plate was screened in triplicate. Eighteen hours after adding drugs, properly titered viral stock diluted in supplemented DMEM media was added at a volume 20 µL per well using a Matrix Wellmate (Thermo Scientific). The multiplicity of infection (MOI) was ~0.5. Forty-eight hours after adding the virus, 30 µL supernatant from the infected plates (the part 1 plates) was transferred into a new set of plates that were seeded the previous day with 1,500 cells in 15 µL supplemented DMEM media per well (the part two plates). This transfer was done using the Liquidator 96-well pipettor (Rainin). The plates were spun at 1,000 r.p.m. for 5 min. The cells in the part 1 plates were then fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 and subsequently washed twice with PBS and incubated with supernatant of p24 Hybridoma culture (183-H12-5C) (NARRRP, contributed by B. Chesebro and H. Chen) diluted in buffer containing 10 µM Tris-HCl (pH 7.5), 150 µM NaCl, 2 µM EDTA and 1% FBS at 4 °C overnight. The next day, after three washes with PBS, cells were incubated with 1:1,000 diluted Alexa Fluor 488 goat anti-mouse IgG antibody at room temperature for an hour. Cells were washed twice and Hoechst 33342 (Sigma-Aldrich) was used to stain the nuclei for total cell count. The cells were imaged using an ImageXpress Micro microscope (Molecular Devices) with 4 × magnification at two wavelengths: 488 nm for the FITC-labeled secondary antibody bound to the anti-p24 primary antibody, and 350 nm for nuclei staining by Hoechst 33342. Images were analyzed using the MetaXpress software npg (Molecular Devices). The part 2 plates were fixed, permeabilized, stained and imaged in the same fashion at 48 h post-infection. Data analysis was done to calculate the "robust" Z score of the infection rate to adjust for the plate-toplate variation 32 . Briefly, the absolute deviation (AD) of each well w is defined as the absolute difference between the infection rate of w and the median infection rate of the plate (M p ).
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The median absolute deviation for each plate (MAD P ) is the median of the absolute differences taken over all wells on a plate.
Then, the "robust" Z score for well w on plate p is
The total number of cells in each well was normalized to the plate average and those wells with less than half the plate average cell count were considered potentially toxic. In a separate screen that focused only on synergistic pairings with glucocorticoids, 1,000 cells/19 µL supplemented DMEM were seeded into each well of fresh 384-well plates. The next day, 100 nl of 10 × diluted source library consisting of one drug per well was pin-transferred into each well so the final concentration of the drug was 0.5-1 µg/ml. Next, 1 µL of prednisolone diluted in DMEM was added to each well to reach a final concentration of 2 µM. The remaining steps (adding virus and immunostaining) were the same as in the MuSIC screen as described above.
Testing anti-HIV activity in the Jurkat reporter cell line JLTRG. 100 µL of JLTRG cells (10 5 cells/ml) 33 (NARRRP, contributed by O. Kutsch) grown in RPMI 1640 media supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 50 U/ml of penicillin and 50 µg/ml streptomycin were seeded into each well of fresh 96-well plates (Corning catalog # 3603). Eighteen hours after drug treatment, HIV virus was added to the wells with MOI ~0.5. Three days post-infection, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, stained for nuclei using Hoechst 33342 and imaged using an ImageXpress Micro microscope (Molecular Devices) with 4 × magnification at two wavelengths: 488 nm for GFP and 350 nm for nuclei stained by Hoechst 33342. Images were analyzed using the MetaXpress software.
P24 ELISA assay using PBMCs. PBMCs from three different donors were purchased from Lonza and cultured in RPMI 1640 media supplemented with 10% fetal bovine serum and 40 U/ml recombinant interleukin 2 (IL2) (NARRRP, contributed by Roche), 2 mM lglutamine, 50 U/ml of penicillin and 50 µg/ml streptomycin and were housed in T75 flasks (Corning). 4 µg/ml phytohemagglutinin (PHA) (Sigma-Aldrich) were supplemented to the culture to stimulate PBMCs and the macrophages attached to the bottom of flasks were removed by changing flasks. For the ELISA assay, 10 5 PBMCs in 100 µL of media were plated into each well of fresh 96-well plates. Drugs properly diluted in RPMI 1640 media were added into the wells at a volume of 50 µL, producing a final volume of 150 µL. Eighteen hours after drug treatment, HIV IIIB virus stock containing 5 ng p24 was diluted in DMEM media to make 50 µL final volume and then added into each well, increasing the total volume to 200 µL. The cells were spun at 2,000g for 2 h at room temperature to boost infection 34 . Seven days after viral infection, the cells were spun down and a portion the supernatant was taken out of the plate and diluted and measured for p24 concentration by ELISA (Alliance p24 ELISA assay kit, PerkinElmer). The cells were measured for viability with the CellTiter Glo assay kit (Promega) following the manufacturer's instructions.
BlaM assay to measure HIV entry. BlaM-vpr containing HIV NL4-3 virus (BlaM-vpr-NL4-3) was generated by transfecting a 10-cm plate of 293T cells (~4 × 10 6 cells) with 10 µg pNL4-3 (NARRRP), 3.4 µg pCMV-BlaM-vpr (Addgene plasmid 21950, generated by W. Greene) and 1.7 µg pAdVAantage (Promega) using the TransIT-293 Transfection Reagent (Mirus) following the manufacturer's instructions. SupT1 cells were resuspended in BlaM media (CO 2 -independent media + 10% fetal bovine serum + 4 mM l-glutamine) at a density of 1 × 10 6 cells/ml and added to each well of a 96-well v-bottom plate (100 µl). The next step was to spin and remove media and resuspend the cells in 100 µl of 200 ng p24/ml BlaM-vpr-NL4-3 virus. Spinoculation at 1,200g in 4 °C for 2 h was used to boost infection. Cells are then spun down and media was removed before two washes with BlaM media. The cells were then resuspended in 100 µl BlaM media and moved to black-walled, clear-bottomed 96-well plates. Plates were incubated in a 37 °C incubator for 4 h to allow fusion. A Gene-Blazer assay (Invitrogen) was subsequently done according to the manufacturer's instructions. Plates were sealed and incubated in the dark at room temperature for 16 h before being read on a plate reader using a 405-nm excitation filter and detection wavelengths at 460 nm (coumarin) and 535 nm (fluorescein).
Drug titration experiments to validate drug synergy. For the part 1 assay, 750 MAGI cells in 20 µL supplemented DMEM were added to each well of fresh, 384-well plates. The next day, 2.5 µL of each drug or DMSO diluted in DMEM was added into each well to make a final volume of 25 µL. Usually, a 10 × 6 concentration matrix was tested with one drug at ten different concentrations and the other drug at six different concentrations. Each dose combination has four repeats. Eighteen hours later, 15 µL of properly diluted virus in DMEM media was added to each well (MOI = 0.5-1). The staining and the part 2 assay were done the same way as described above.
Late-RT and 2-LTR analyses. In a 12-well plate, 10 5 MAGI cells were seeded in 1 mL supplemented DMEM media per well overnight. Drugs were added the second day. Eighteen hours after drug treatment, VSV-G pseudotyped NL4-3 HIV was added to the cells at MOI ~0.5. Twenty-four hours after infection, cellular DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen). We performed quantitative RTPCR as described 35 and the results were normalized to cellular mitochondria DNA. For SupT1 cells, 3 × 10 5 SupT1 cells were seeded in 1 mL supplemented RPMI 1640 media before drug treatment. The following steps were the same as those for MAGI cells.
Computational analysis for building the drug synergy network. We adapted a method used for measuring gene-gene interaction strength in a yeast E-MAP study to estimate drug-drug synergy 23 . To quantify the synergy, it was necessary to estimate the effectiveness of individual drugs. We took advantage of the fact that in the secondary screen (screening the drug pairs from the top pools in the primary screen of ten-drug combinations), each individual drug appeared at least 9 times and 13 times on average in combination with different drugs. We derived a measure for single-drug activity based on the average activity taken over all the drug pairs containing a given drug. The details of the calculation are described below.
Normalization for infection rates and total cell number. The infection rates and total cell numbers are normalized to correct for differences in the experimental conditions on different plates. The B-score method was used to normalize the plate specific effect as well as the positional effect (column effect and row effect) 32 . We used two functions in MATLAB, namely medianPolish and mad to conveniently calculate the B score. medianPolish can be used to calculate the residual r for each well in a plate, which quantifies the drug effect after correcting for plate bias and positional effects. Given a vector of r values for an entire plate, mad can be used to calculate the median absolute deviation (MAD) for the plate. 
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The final B score for a well w was computed as the median B-score across the three replicate plates containing w.
Scoring drug interaction.
We quantified the interaction between two drugs based on a strategy similar to the S score method previously established 23 where: u exp = mean of the B-score normalized infection rates taken over all replicates of AB, which is an estimate of W AB n exp = number of replicates of AB (typically n exp = 3) u con = estimate of W A + W B . See below for details on computation. n con = the number of pairs containing drug A or drug B s var = (v exp × (n exp -1) + v con × (n con -1)) ÷ (n exp + n con -2) where:
v exp = variance across the B-score normalized infection rates of all AB replicates v con = the sum of the variance of all the pairs containing drug A and the variance of all the pairs containing drug B Our model is based on the assumption that significant drug interaction is rare; hence, the infection rate of a typical drug pair is just the sum of its two components and error (whose mean estimate is 0). Using these assumptions, we can estimate the synergy between drugs A and a typical drug X via 
To estimate W AX , we compute the trimmed mean of the B-score normalized infection measurements taken over every drug pair containing drug A, including replicates. The trimmed mean u AX is the standard mean after excluding measurements in the top and bottom 20% of measurements. The estimate u BX ′ for W BX ′ is computed in the same way. However, given the set of all drugs X that appear with drug A, and the set of all drugs X′ that appear with drug B, it is not guaranteed that every possible drug pair XX′ was tested in the secondary screen. Therefore, we were forced to compute the trimmed mean u XX ′ over whatever subset was available for the given pair AB. In the worst case, there exists at least 28 pairs XX′ for any pair AB tested in the secondary screen. This is because any pair tested in the secondary screen was the result of a "hit" well in the primary screen, where wells contained ten drugs each. The deconvolution of the primary screen well containing AB produces 45 pairs in total, all of which were tested in the secondary screen. Of the 45 pairs, one is AB, 8 more can be represented as AX, another 8 correspond to BX′ and the remaining 28 wells are valid XX′ pairs which are guaranteed to exist in the secondary screen. Using these estimates, we can write
where: n AX = number of drug pairs containing drug A n BX = number of drug pairs containing drug B n XX = number of drug pairs XX such that AX and BX′ exist in the secondary screen v AX = variance of all drug pairs containing drug A v BX = variance of all drug pairs containing drug B v XX = variance of all drug pairs XX such that AX and BX exist in the secondary screen The sign of the S score reflects the type of interaction. A negative score denotes a synergistic interaction and a positive score denotes an antagonistic interaction. The distribution of S scores largely conforms to normal distribution, which indicates that the S-score calculation is not obviously biased. (Supplementary Figs. 13 and 14) Building the network of synergistic drug pairs. After scoring the interactions between drug pairs, an interaction network was built to illustrate connections between high performing drugs. From the part one assay result, highly effective drug pairs with highly confident synergistic interactions were selected-namely, drug pairs with infection rates in the lowest 5 percent of all infection rates (Supplementary Fig. 15 ) and with S score ≤ −2 ( Supplementary Fig. 13) . From this set, we excluded drug pairs that fell into the bottom 15% of the cell count distribution due to potential cytotoxicity or a biased infection rate due to low cell count (Supplementary Fig. 16 ). The selected drug pairs were then broken into individual drugs and only those drugs appearing in ≥3 selected pairs were kept. This was to increase the confidence of the selected drugs as effective drugs usually synergize with multiple other drugs. Forty-two drugs met these criteria. In Figure 4 , on the left, each drug is shown as a node. The size of each node reflects how frequently the drug interacts with others (node degree); yellow nodes represent drugs with previously detected anti-HIV activity; nodes marked with a red outer circle are anti-inflammatory drugs. The edges indicate a synergistic interaction with S score ≤ -2. The width of each edge correlates with the degree of synergy: the thicker the edge, the stronger the synergy.
The results of the part 2 screen were processed in a similar way with two more conditions: (i) we excluded pairs which had low total cell counts in either part 1 or part 2 and (ii) drug pairs were excluded if they were highly effective in part 1. Specifically, we selected drug pairs with infection rate in the bottom 5th percentile (Supplementary Fig. 17 ) and an S score ≤ -1.5 (we lowered this cutoff compared to part 1 as the S score distribution in part 2 is narrower) (Supplementary Fig. 14) . Only drugs with ≥3 interactions were retained. To filter out toxic compounds or biased infection rates due to low cell count, measurements with cell counts in the lowest 20th percentile in either the part 1 or part 2 assays were discarded (Supplementary Figs. 16  and 18) . Additionally, drug pairs with infection rates in the bottom 15th percentile of the part 1 assay were discarded so that we selected only those drug pairs unique to the part 2 assay. In this network of 37 selected drugs (Fig. 4,  right) , each node is a drug. Node size reflects how frequently this drug interacts with others; yellow nodes represent known anti-HIV; blue nodes represent anti-HIV drugs newly discovered by our experiments; nodes marked with a red circle are known anti-inflammatory drugs; the width of each edge correlates with the degree of synergy: the thicker the edge, the stronger the synergy. The network plot was made using the Cytoscape software package 36 .
Synergy quantification by the CI model, the Bliss independence model and the HSA model. The CI 20 model, the Bliss Independence model (BI) 13 and the HSA model 7 are the most commonly used methods to evaluate synergy between drug combinations. The CI model is based on the Loewe Additivity model. The CI calculated in Figure 2F was calculated using the CalcuSyn software package (Biosoft) following the instructions therein.
For BI model calculation, the expected effect is given by We use E DIF = E OBS -E EXP to evaluate the interaction of the drug pair. Based on BI's definition, when E DIF > 0, the two drugs interact synergistically, when E DIF < 0, the two drugs have an antagonistic interaction and when E DIF = 0, they do not interact at all 37 . To account for experimental variation, we consider two drugs synergistic only if E DIF > 0.1 for at least three different concentration combinations. The validated, synergistic drugs can be found in Supplementary Table 5 .
The maximum E OBS and maximum E DIF values from the titration experiments are also shown. The HSA model is similar to the Bliss model, except E EXP = Max (E ↓ A,E ↓ B). Here, we also require that E DIF > 0.1 for at least three different concentration combinations for two drugs be called synergistic.
